Developing novel medicines to make

a profound impact
on mental health care

Addressing major unmet needs in mental health, with pharmacology rooted in emerging and clinically validated biology

Syremis Therapeutics is a clinical-stage biopharmaceutical company developing novel medicines to make a profound impact on the treatment of mental health. The company’s neuropsychiatric pipeline is rooted in emerging and clinically validated mechanisms, including muscarinic M1/M4 agonism and next-generation NMDA antagonism.

Schizophrenia and other psychotic disorders remain among the most debilitating and underserved conditions worldwide, with more than 20 million people affected and facing considerable disability, elevated relapse rates, and reduced life expectancy. Despite decades of need, current treatments often fall short in both efficacy and tolerability. Syremis is committed to developing novel and better treatments for these conditions. The lead program, ST-905, is a dual M1/M4 agonist in Phase 1 development for schizophrenia and other psychiatric conditions.

The company is also advancing ST-901, a novel NMDA antagonist currently in IND-enabling studies. ST-901 will be developed for major depressive disorder and bipolar depression, two conditions with significant unmet need and high societal impact.

PIPELINE

Discovery
Preclinical
Phase 1
Phase 2

ST-905

M1/M4 muscarinic agonist

Schizophrenia
Schizophrenia

ST-901

NMDA antagonist

MDD
MDD
ST-905

ST-905 is a potent M1/M4 muscarinic agonist currently in 
Phase 1. ST-905 is being developed for schizophrenia and other serious neuropsychiatric conditions.

+ MORE
ST-901

ST-901 is a novel NMDA antagonist currently in IND-enabling 
studies. ST-901 is being developed for major depressive disorder and bipolar depression.

+ MORE

LEADERSHIP

Elisabeth Kogan
CEO and co founder
+ MORE
Elena Kagan
Chief Development
Officer and co founder
+ MORE
Menashe Levy
Chief Technology
Officer and co founder 
+ MORE
Eli Gendler
Chief Financial Officer
+ MORE
Lior Sahaf
VP Business Development
+ MORE
Orly Eini
VP Human Resources
+ MORE
Efrat Shalom-Berensohn
General Counsel
+ MORE
Martin Himmel
VP Regulatory Affairs
+ MORE

BOARD OF DIRECTORS

Ilan Oren
Chairman
Co-CEO, Dexcel Pharma
+ MORE
Reid Huber
Partner, Third Rock
Ventures
+ MORE
Steve Paul
Former CEO and Chair of
Karuna Therapeutics
+ MORE
Uri Oren
Co-CEO, Dexcel Pharma
+ MORE
Ray Sanchez
Senior Advisor at Bain Capital, former CMO of Cerevel
+ MORE
Elisabeth Kogan
CEO and co founder
+ MORE

SUPPORTED BY LEADING INVESTORS

dexcel2
Mask group
bain
GV2
pictet
qvt
Reid Huber PhD
Partner, Third Rock Ventures

Reid Huber joined Third Rock in 2018 as a Partner, bringing more than 25 years of leadership and experience to the role. He focuses on the formation, development, and strategy of Third Rock’s portfolio companies. Reid served as Interim CEO of MOMA Therapeutics until the appointment of Dr. Asit Parikh in Spring of 2021, of Rapport Therapeutics until the appointment of Abe Ceesay in the Spring of 2023, and of Merida Biosciences until the appointment of Adam Townsend in the Spring of 2025.


Reid joined TRV from Incyte, where he was a member of the founding scientific team and most recently served as executive vice president and chief scientific officer. At Incyte, he held roles of increasing responsibility across multiple therapeutic areas in both drug discovery and clinical development. In 2011, he assumed responsibility for the company’s research and early development activities. Before joining Incyte, Reid held scientific research positions at DuPont Pharmaceuticals and Bristol-Myers Squibb from 1998 to 2002.


He received his Ph.D. in molecular genetics from the Washington University School of Medicine and held predoctoral and postdoctoral fellowships at the National Institutes 
of Health.


Reid is a board director at Rapport Therapeutics, Merida Biosciences, Terremoto, Synnovation Therapeutics, MOMA Therapeutics, Asher Biotherapeutics, and a board observer at insitro.